The appeals court's decision in Gilead Sciences v. Meritain Health is unambiguous: you cannot import untraceable medicine with foreign-language labels, hand it to American patients, and call it equivalent to an FDA-approved medicine. Track-and-trace is a cornerstone of why the U.S. drug supply chain is the safest in the world, and it is not optional.

The real victims here are American patients — workers enrolled in health plans that made a calculated decision to endanger them for cost savings. Those patients received medicines with labels in foreign languages they could not read from sources that could not be traced back to the manufacturer if something went wrong. That is a clear patient safety failure.

PSM congratulates Gilead Sciences on a decisive, comprehensive victory. We look forward to the lower court proceedings and to real accountability for businesses built on putting patients at risk.

Learn more about the case:

• Read the appeals court decision
• Read our case overview